<DOC> 
<DOCNO>1040805_business_story_3583654.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
 Thursday, August 05, 2004 				 US tonic for Ranbaxy plan
 OUR CORRESPONDENT 																								New Delhi, Aug. 4: Domestic pharmaceutical major Ranbaxy has received the final approval to market Fluconazole tablets and suspension in the US market.																								The office of generic drugs, US Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Diflucan (innovator drug) of Pfizer Central research.																								Total market sales for Fluconazole were $741 million (March 2004). Tablet sales represented a total of $469 million and the suspension $28 million.																								Diflucan (Fluconazole) is indicated for the treatment of vaginal candidiasis (vaginal yeast infections due to Candida), oropharyngeal and oesophageal candidiasis and cryptococcal meningitis.																								Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone-marrow transplantation who receive cytotoxic chemotherapy and or radiation therapy. 
</TEXT> 
</DOC>